Information Provided By:
Fly News Breaks for July 22, 2019
Jul 22, 2019 | 07:50 EDT
Laidlaw analyst Francois Brisebois initiated Galmed with a Buy rating and $25 price target, citing his belief that the company's Aramchol could be a "great candidate" for a combination treatment for Nonalcoholic Steatohepatitis, or NASH. Galmed expects to initiate a Phase 3/4 trial of Aramchol in Q3 and report data from its first part by the end of 2022, Brisebois noted.
News For GLMD From the Last 2 Days
There are no results for your query GLMD